An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer (NSCLC)
Patients with known wild-type EGFR gene; patients with unknown EGFR mutation status are allowed if they fulfil the following criteria:
squamous cell carcinoma lung cancer histology, and
current smoker, or former smoker who has stopped smoking less than 10 years ago and has had a total of \>15 pack-years of smoking
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
Patients having failed one prior chemotherapy regimen and eligible for a second-line treatment with Tarceva
You may not be if
Current treatment with an investigational drug or participation in another investigational study
Severe or uncontrolled systemic disease, active infection, concomitant malignancy or a second primary malignancy except for in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin
Clinically active interstitial lung disease
Recent myocardial infarction or unstable angina
Progressive or uncontrolled brain metastases
Clareo Health | An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)
